Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected.

Reports Q4 revenue $4.55M vs. $10.9M last year. “In 2024, Recursion made a transformative leap with the largest TechBio merger in history, ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of $178.9 million in its fourth quarter. On a per-share basis, the Salt Lake City-based ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...